Migraine patients who received CGRP monoclonal antibodies after 3+ lines of failed preventive therapy reported better quality of life than those remaining on standard-of-care preventives, particularly in Europe.
Enhanced HRQoL with CGRP mAbsIn patients who failed 3+ preventive migraine treatments, CGRP antibodies improved quality of life vs standard care
What the researchers found
Patients with 3+ lines of prior preventive therapy who received CGRP mAbs (including galcanezumab) showed enhanced health-related quality of life compared to standard-of-care preventives in European and overall populations.
Why it matters
Patients who've failed multiple migraine preventives represent the most burdened group. Demonstrating real-world quality-of-life improvements with CGRP antibodies in this population validates their role as a meaningful therapeutic advance, not just another option.
The numbers in context
Survey data from US and Europe; compared CGRP mAbs vs. standard preventive medications on quality of life, disability, and work productivity measures.
How the study worked
Cross-sectional survey using the Adelphi Migraine Disease Specific Programme (May 2022 - June 2023). 557 physicians completed record forms for 6,723 patients across the US and Europe. 4,036 patients with preventive treatment history analyzed using t-tests, Fisher's exact test, and Mann-Whitney U test.
Who was studied
US and European migraine patients on preventive treatments (CGRP mAbs vs. standard of care)
What this study cannot tell us
Cross-sectional design — cannot establish causation. Potential physician selection bias in patient enrollment. Quality-of-life difference not significant in US subgroup. Industry-funded (Eli Lilly). Patient self-report may be influenced by expectations of newer therapy.
How to read the evidence
Moderate evidence — large cross-sectional survey with real-world data, but non-randomized design cannot establish causation. Industry-funded.
When this study was published
Published in 2024 with data from 2022-2023. Reflects mature CGRP antibody adoption patterns.
The bigger picture
These real-world patient-reported outcomes complement clinical trial data by showing that CGRP antibodies don't just reduce headache days — they meaningfully improve daily life, work productivity, and disability for the patients who need it most.
Questions still open
- Why did the US subgroup not show significant PRO differences — is it access, patient characteristics, or sample size?
- Do CGRP antibodies maintain quality-of-life benefits beyond 12 months?
- Would similar benefits be seen with gepants (oral CGRP inhibitors) in this treatment-refractory population?
Common questions
Do CGRP antibodies actually improve daily life for people with migraine?
Are CGRP antibodies only for people who've tried everything else?
Read the original research
Patient-reported outcomes related to migraine burden among patients treated with standard-of-care preventive medications or calcitonin gene-related monoclonal antibodies: a United States and Europe cross-sectional survey.
Current medical research and opinion, 40(12), 2179-2190
Citation
Varnado, Oralee J; Jackson, James; Scharf, Lucas; Kim, Gilwan; Cotton, Sarah. (2024). Patient-reported outcomes related to migraine burden among patients treated with standard-of-care preventive medications or calcitonin gene-related monoclonal antibodies: a United States and Europe cross-sectional survey.. Current medical research and opinion, 40(12), 2179-2190. https://doi.org/10.1080/03007995.2024.2427884